Skip to main content

Global Regenerative Medicine Market Size [2022-2028] | to Reach USD 151,949.5 Million, with 26.1% CAGR

Key Companies in Regenerative Medicine Market are Integra LifeSciences Corporation, CELGENE CORPORATION, Medtronic, American CryoStem Corporation, Tissue Regenix, Avita Medical, Osiris Therapeutics, Inc., Wright Medical Group N.V., Smith & Nephew, Integra LifeSciences Corporation, Other players

Pune, India, Feb. 02, 2022 (GLOBE NEWSWIRE) — The global regenerative medicine market is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. According to a report published by Fortune Business Insights, titled “Regenerative Medicine: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at USD 23,841.5 Mn in 2018. Fortune Business Insights states that the market will reach USD 151,949.5 Mn by the end of 2026, thereby exhibiting a CAGR of 26.1%.

Recent developments in treatment of acute and chronic diseases can be attributed to advances in regenerative medicines. Regenerative medicine mainly focus on identifying the root cause of the disease and aims at locating, repairing, and regenerating the non-functioning body cells. As most of the chronic and acute diseases are inclined towards the elderly and geriatric population, the growing geriatric population serves growth of the global regenerative medicine market in the coming years. The ability of regenerative medicine to reduce the burden for some of the most severe chronic diseases will create a high demand for the products in the coming years. Furthermore, applications of regenerative medicine in treatment of diabetic ulcers and chemotherapy will favor the growth of the market in the forthcoming years.


Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970


Novartis Receives EU Approval for Luxturna

The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to treat severe life-threatening diseases in an efficient manner has created a huge demand for the products across the world. Increasing drug approvals have contributed to the rising uptake for regenerative medicines. In 2018, Novartis received usage approval from the European Union for its latest regenerative medicine ‘Luxturna’. The drug was used to treat and restore sight for people with vision impairment. Luxturna was widely useful in treatment of rare retinal diseases. Fortune Business Insights states that the approval for Luxturna will contribute to the growth of the global regenerative medicine market in the forthcoming years.

Integra LifeSciences’ Latest Product Offering Will Favor Market Growth

The advancements in regenerative medicine have fueled their demand across the world. Increasing product launches have contributed to the rising uptake of regenerative medicine across the world. In 2017, Integra LifeSciences announced the launch of Integra Dermal Regeneration Template Single Layer ‘Thin’. The product was aimed at repairing dermal defects in a one-step procedure. The medicine will also aid in reducing hospital stays. Fortune Business Insights has identified Integra’s latest product offering as a major market growth driver. The report includes product launches, similar to Integra’s latest medicine and gauges the impact of these products on the global regenerative medicine market in the coming years.

Fortune Business Insights some of the leading companies that have made significant growth contributions to the global market. Besides this, the report identifies some of the attractive business strategies that have been adopted by renowned companies in the world. Some of the leading companies that are operating in the market are Integra LifeSciences Corporation, CELGENE CORPORATION, Medtronic, American CryoStem Corporation, Tissue Regenix, Avita Medical, Osiris Therapeutics, Inc., Wright Medical Group N.V., Smith & Nephew, and Integra LifeSciences Corporation.


To get to know more about the short-term and long-term impact of COVID-19 on this market,

Please Visit: https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

List of Key Players in Regenerative Medicine Market:

  • Integra LifeSciences Corporation
  • CELGENE CORPORATION
  • Medtronic
  • American CryoStem Corporation
  • Tissue Regenix
  • Avita Medical
  • Osiris Therapeutics, Inc.
  • Wright Medical Group N.V.
  • Smith & Nephew
  • Integra LifeSciences Corporation
  • Other players


Ask for Customization of this Report: 

https://www.fortunebusinessinsights.com/enquiry/customization/regenerative-medicine-market-100970

Major Table of Contents:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence and incidence of diabetes, by key countries
    • Advancements in insulin delivery devices
    • Pricing Analysis, by key players
    • Technological Advancements
    • Key mergers & acquisitions, by key players
  • Global Regenerative Medicine Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Product
      • Cell Therapy
      • Gene Therapy
      • Tissue Engineering
      • Platelet Rich Plasma
    • Market Analysis, Insights and Forecast – By Application
      • Orthopedics
      • Wound Care
      • Oncology
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospitals
      • Clinics
      • Others
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia pacific
      • Latin America
      • Middle East & Africa
  • North America Regenerative Medicine Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Product
      • Cell Therapy
      • Gene Therapy
      • Tissue Engineering
      • Platelet Rich Plasma
    • Market Analysis, Insights and Forecast – By Application
      • Orthopedics
      • Wound Care
      • Oncology
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospitals
      • Clinics
      • Others
    • Market Analysis, Insights and Forecast – By Country
      • U.S.
      • Canada

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.